Significance of soluble PD-L1 in melanoma patients

可溶性 PD-L1 在黑色素瘤患者中的意义

• 批准号: nhmrc : 1083496
• 负责人: Dr Matteo Carlino
• 金额: $ 37.42万
• 依托单位: The University of Newcastle
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2015
• 资助国家: 澳大利亚
• 起止时间: 2015-01-01 至 2018-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/significance-soluble-pd-melanoma-patients/518938
• 关键词: Significance; soluble; PD; L1; melanoma

A class of new immunotherapy drugs called “antibodies of immune checkpoints” can lead to long-lasting melanoma regression, but they are only beneficial to a subset of patients. This project will potentially identify the increased expression of a protein called PD-L1 in the blood as a biomarker predictive of responses of melanoma patients to these new drugs. The results will be instructive for selection of patients for the treatment.

一种名为“免疫检查点抗体”的新型免疫治疗药物可以导致长期的黑色素瘤消退，但它们只对一部分患者有益。该项目将有可能确定血液中一种名为PD-L1的蛋白质的表达增加，作为预测黑色素瘤患者对这些新药反应的生物标志物。其结果将对选择患者进行治疗具有指导意义。